入排依据:The record is a commentary on the original phase III trial (Jenner et al.). It does not contain the primary formal results with explicit time-to-event endpoint data (e.g., OS, PFS, Kaplan-Meier, HR). Therefore, it is not eligible as an original result report for KM digitization. The 'is_eligible' criterion is set to null because the metadata cannot establish the presence of the required time-to-event endpoint in this specific document.
摘要
摘要
In multiple myeloma (MM) long-term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (NTE) patients enrolled in the Myeloma XI trial. Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial. Br J Haematol. 2023;201:276-288.
KM 提取结果
0 个 Figure · 0 个 KM 面板